***Background.*** Recent data suggest that healthcare-associated invasive methicillin-resistant *S. aureus* (MRSA) infections are declining in the US (JAMA Intern Med 2013;173:1970). However, such infections are the minority of SA disease. Few studies have examined recent trends in epidemiology of SA clinical isolates that include susceptible, community-onset and non-bloodstream isolates. We performed multicenter SA surveillance in 2009, 2011 and 2013.

***Methods.*** We collected SA isolates from July-December in 2009, 2011 and 2013 from a geographically representative sample of US hospitals. 28 centers participated in all 3 surveys, each submitting up to 100 consecutive, unique (1 isolate/patient) clinically-significant SA, with demographic information, during each survey. Susceptibility testing was performed using CLSI methods and *mec*A PCR. Pulsed field gel electrophoresis (PFGE), spa and SCC*mec* typing, and *pvl* detection were performed on all MRSA. We defined as hospital-onset (HO) those SA from cultures obtained \>48 h after admission.

***Results.*** A total of 8377 SA isolates were collected (2009:2828, 2011:2767, 2013: 2782). Age distribution of pts was \< 5 (6%), 6-20 (10%), 21-64 (59%), and \> 65 years (23%), and 55% were male. The most common specimen source was wound/abscess (52%), followed by bloodstream (25%). The % MRSA decreased over time, from 53% of isolates *mec*A + in 2009-2011 to 46% in 2013. Only 15% of SA were HO: among MRSA, the % that were HO decreased from 15-16% in 2009-2011 to 12% in 2013. HO-MRSA accounted for only 5% of all SA clinical isolates in 2013. The USA300 MRSA PFGE type predominated in all three surveys, and by 2013 a single spa type (t008) accounted for 54% of all MRSA, followed by t002 (17.2%), with no other spa type accounting for more than 2% of MRSA. High level mupirocin resistance increased among SA/MRSA from 1.8/2.2% in 2009 to 2.6/3.9% in 2013.

***Conclusion.*** Consistent with reports of declining HO-MRSA infection rates, our microbiology lab-based surveillance reveals that a decreasing proportion of all SA clinical isolates are MRSA or hospital-onset. Rates of resistance to mupirocin, an agent used often in HO-MRSA prevention programs, are rising. Strategies to prevent SA infections beyond HO-MRSA will be needed to substantially impact the burden of SA disease.
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